Grant: CIHR Fellowship
Direct Payment
$150,000.00
Regulation of central nervous system S1P production and the role of S1P signaling in Bergmann glia in an animal model of multiple sclerosis.
FY 2011-12
Summary
Sphingosine-1-phosphate (S1P) is a signaling molecule that regulates many cellular processes. The concentration of S1P increases in the central nervous system (CNS) during multiple sclerosis (MS), but the source of this increase and its role in the CNS is not known. Recently, Fingolimod (FTY720), a drug targeting four of the five S1P receptors (S1PRs), was approved for clinical use in treating relapsing-remitting MS. Despite its spectacular success, due to the broad expression of S1PRs on many cells throughout the body, treatment has serious side-effects. Identifying the cells involved in pathological S1P signaling in MS would allow for better-targeted therapies that block S1P's destructive effects but leave its normal functions unaltered.
S1PRs are expressed on many cells within the CNS, and recent work suggests that FTY720 treatment may relieve disease through blocking S1PR1 on astrocytes, a CNS-restricted cell type. We want to understand how S1P levels are regulated in the CNS, and to characterize its effects on astrocytes. Using mice in which individual cell-types are rendered unable to produce S1P, we will identify the cellular source of S1P production in experimental autoimmune encephalomyelitis (EAE, an animal model of MS). We will determine the cell responsible for S1P degradation within the CNS during EAE. FInally, we will probe the effects of S1PR signaling on astrocyte function, and explore the possibility that S1P signaling allows astrocytes to guide infiltrating immune cells along their surface, deeper into CNS tissue.
Many therapeutic opportunities will emerge once these aspects of CNS S1P biology are elucidated, and the CNS- or cell type-specific targets identified will mean better-directed therapies with fewer side-effects.
Department
Program
CIHR Fellowship
Recipient
Location
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
242447
Name
Summers Deluca Leslie E
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Regulation of central nervous system S1P production and the role of S1P signaling in Bergmann glia in an animal model of multiple sclerosis.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Animal Models; Autoimmunity; Bone Marrow Chimeras; Central Nervous System; Fluorescence Microscopy; Immune Cell Trafficking; Immunology; Inflammation
Abstract
Sphingosine-1-phosphate (S1P) is a signaling molecule that regulates many cellular processes. The concentration of S1P increases in the central nervous system (CNS) during multiple sclerosis (MS), but the source of this increase and its role in the CNS is not known. Recently, Fingolimod (FTY720), a drug targeting four of the five S1P receptors (S1PRs), was approved for clinical use in treating relapsing-remitting MS. Despite its spectacular success, due to the broad expression of S1PRs on many cells throughout the body, treatment has serious side-effects. Identifying the cells involved in pathological S1P signaling in MS would allow for better-targeted therapies that block S1P's destructive effects but leave its normal functions unaltered.
S1PRs are expressed on many cells within the CNS, and recent work suggests that FTY720 treatment may relieve disease through blocking S1PR1 on astrocytes, a CNS-restricted cell type. We want to understand how S1P levels are regulated in the CNS, and to characterize its effects on astrocytes. Using mice in which individual cell-types are rendered unable to produce S1P, we will identify the cellular source of S1P production in experimental autoimmune encephalomyelitis (EAE, an animal model of MS). We will determine the cell responsible for S1P degradation within the CNS during EAE. FInally, we will probe the effects of S1PR signaling on astrocyte function, and explore the possibility that S1P signaling allows astrocytes to guide infiltrating immune cells along their surface, deeper into CNS tissue.
Many therapeutic opportunities will emerge once these aspects of CNS S1P biology are elucidated, and the CNS- or cell type-specific targets identified will mean better-directed therapies with fewer side-effects.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Summers Deluca, Leslie E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~